Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2924)	4/28/2020 12:37:34 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

All numbers are not yet in; Eylea US sale (Beuvo US sale), Libtayo update (BSC), new programs, COVID effect on R&D speed/focus,... Nonetheless, NAbs for SARS-CoV2 is next important one. Maybe data from primate pre-clinical. IMO, more important is dynamic in Dupi sale growth, new indications, size of the COVID effect on sale (so far appears less intense than on other biologic)? So, where from this point? Will see, I do not have crystal boll. I am confident that REGN will move forward withs its business, stepwise with some more efforts on infection diseases (bacterial and viral). Also more prominent rule of RGC.